Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteclarusventures.com
Phone617.949.2200
Employees
DescriptionVenture capital firm

Funds

Total$500M
Clarus Lifesciences III L.P., 2/2014
Clarus Lifesciences II L.P., 1/2008
Clarus Lifesciences I L.P., 1/2005 $500M

Offices

HQ
101 Main Street Suite 1210
Cambridge, MA, 02142
USA
South San Francisco, USA
801 Gateway Boulevard
Suite 410
South San Francisco, CA, 94080
USA

People

Partner
Partner
Venture Partner
Managing Director
Managing Director
Managing Director
Managing Director
Managing Director
Show All People

Tags

Clarus Ventures

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level.

Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds

Recent Milestones

Investments

Company Date Round Size Participants
Catabasis Pharmaceuticals 11/2013Series B$32.4M5
Heptares Therapeutics 6/2013Series B$21M2
NanoString Technologies 5/2013Venture Round$150k3
Pearl Therapeutics 4/2013Private Equity$41.7M4
SFJ Pharmaceuticals 4/2013Private Equity$13M1
Catabasis Pharmaceuticals 2/2013Venture Round$9M4
Avillion 1/2013Venture Round2
NanoString Technologies 12/2012Series E$15.3M7
Pearl Therapeutics 11/2012Series D$65M4
SFJ Pharmaceuticals 10/2012Venture Round$500k1
Pearl Therapeutics 10/2012Private Equity$23.3M4
SFJ Pharmaceuticals 7/2012Private Equity$21M1
Oxford Immunotec 6/2012Venture Round$28M8
SFJ Pharmaceuticals 4/2012Private Equity$35M1
Catabasis Pharmaceuticals 12/2011Series A$8M4
NanoString Technologies 11/2011Series D$20M5
Cleave Biosciences 10/2011Series A$44M6
Restoration Robotics 8/2011Series C$41M4
SARcode Bioscience 7/2011Series B$44M4
Aerie Pharmaceuticals 3/2011Series B$41.4M5
TyRx Pharma 12/2010Venture Round$20M3
Achillion Pharmaceuticals 8/2010Venture Round$50.1M4
TetraLogic Pharmaceuticals 8/2010Series C$32M8
Zogenix 7/2010Venture Round$15M5
FerroKin Biosciences 6/2010Series B$12M5
Oxford Immunotec 5/2010Series D$26M7
Catabasis Pharmaceuticals 4/2010Series A$39M4
Pearl Therapeutics 3/2010Series C$15M3
NanoString Technologies 2/2010Venture Round$15M1
Neomend 1/2010Series D$30M5
Ophthotech 12/2009Series B$30M4
Virdante Pharmaceuticals 11/2009Series A$30M6
Zogenix 10/2009Series B$36M5
NanoString Technologies 6/2009Series C$30M3
Lycera 5/2009Series A$36M4
Aerovance 4/2009Venture Round$38M8
Biolex Therapeutics 10/2008Series D$60M11
ESBATech 8/2008Series B$22M7
Pearl Therapeutics 7/2008Series A$18M4
Zogenix 1/2008Venture Round$18M4
Taligen Therapeutics 1/2008Series B$65M4
Pelikan Technologies 12/2007Series F$69M3
Oxford Immunotec 10/2007Series C$40M6
Sientra 4/2007Series B$85M3
Aerovance 3/2007Series C$60M6
SARcode Bioscience 12/2006Venture Round$29M2
Zogenix 8/2006Series A$60M5
ESBATech 8/2006Series B$41M7

Videos

Sources

  1. Clarus Ventures Raising Smaller Third Fund (pevc.dowjones.com) [edit]
  2. Clarus Ventures Raising Smaller Third Fund (pevc.dowjones.com) [edit]
  3. Clarus Ventures Raising Smaller Third Fund (pevc.dowjones.com) [edit]
  4. Catabasis Pharmaceuticals Completes $32.4M Series B Financing (finsmes.com) [edit]
  5. Heptares Therapeutics Raises $21M In Series B Financing (finsmes.com) [edit]
  6. SEC (sec.gov) [edit]
  7. VC Funding: Q2 2013 source [edit]
  8. VC Funding: Q2 2013 source [edit]
  9. Catabasis raises $9M for PhII-ready drug development program (fiercebiotech.com) [edit]
  10. Avillion Receives Funding from Abingworth and Clarus Ventures (finsmes.com) [edit]
  11. NanoString Technologies Completes $15.3 Million Series E Financing (reuters.com) [edit]
  12. Pearl Therapeutics Raises $65M in Series D Financing (finsmes.com) [edit]
  13. VC funding: Q4 2012 [edit]
  14. VC funding: Q4 2012 [edit]
  15. VC Funding: Q3 2012 source [edit]
  16. Oxford Immunotec Raises $28M in Equity Financing (finsmes.com) [edit]
  17. VC Funding: Q2 2012 source [edit]
  18. Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing (catabasispharma.com) [edit]
  19. NanoString Grabs $20M From GE, Former Genzyme CEO to Pursue Molecular Diagnostics (xconomy.com) [edit]
  20. Cleave Biosciences Raises $42M in Series A Financing (finsmes.com) [edit]
  21. Restoration Robotics Raises $41M in Series C Financing (finsmes.com) [edit]
  22. SARcode Bioscience Closes $44M Series B Financing (finsmes.com) [edit]
  23. SEC (sec.gov) [edit]
  24. TYRX, Inc. Raises $20 Million in Private Financing (tyrx.com) [edit]
  25. Achillion Announces Private Placement of $50 Million (ir.achillion.com) [edit]
  26. TetraLogic nabs $32M round for lead cancer therapy Read more: TetraLogic nabs $32M round for lead cancer therapy (fiercebiotech.com) [edit]
  27. Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capital (zogenix.com) [edit]
  28. FerroKin rounds up $12M for iron overload treatment Read more: FerroKin rounds up $12M for iron overload treatment - FierceBiotech http://www.fiercebiotech.com/story/ferrokin-rounds-12m-iron-overload-treatment/2010-06-18?utm_medium=rss&utm_source=rss#ixz (fiercebiotech.com) [edit]
  29. Oxford Immunotec, Ltd.: Series D $26M (onbiovc.com) [edit]
  30. Catabasis lands $39M Series A for diabetes programs (fiercebiotech.com) [edit]
  31. Pearl Therapeutics, Inc.: Series C $15M (onbiovc.com) [edit]
  32. EDGAR [edit]
  33. Neomend Closes $30M Funding Round (finsmes.com) [edit]
  34. Ophthotech nabs $30M round to fund AMD trial (fiercebiotech.com) [edit]
  35. Virdante Pharmaceuticals, Inc.: Series A $30M (onbiovc.com) [edit]
  36. SEC D (sec.gov) [edit]
  37. NANOSTRING® TECHNOLOGIES CLOSES $30 MILLION SERIES C FINANCING TO ACCELERATE THE COMMERCIALIZATION OF ITS LEADING EXPRESSION PROFILING PRODUCTS (freshnews.com) [edit]
  38. Lycera Corp.: Series A $36M (onbiovc.com) [edit]
  39. Aerovance inhales $38M for asthma drugs (venturebeat.com) [edit]
  40. Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C (mitsuiventures.com) [edit]
  41. ESBATech rounds up $22M in second round (fiercebiotech.com) [edit]
  42. Pearl Therapeutics ups its first round funding (venturebeat.com) [edit]
  43. Zogenix Raises $18 Million in Preferred Stock Financing (zogenix.com) [edit]
  44. Taligen Therapeutics Secures Series B Financing (taligentherapeutics.com) [edit]
  45. Pelikan Tech to push “finger friendly” diabetes testing (venturebeat.com) [edit]
  46. Oxford Immunotec Completes $40M Financing (oxfordimmunotec.com) [edit]
  47. Sientra, device maker for plastic surgery, raises $85M (venturebeat.com) [edit]
  48. Aerovance, asthma treatment company, finishes raising $60M (venturebeat.com) [edit]
  49. SARcode secured $25 million in financing (sarcode.com) [edit]
  50. Zogenix, Inc. Raises $60 Million In Series A Venture Financing; Names Board of Directors (zogenix.com) [edit]
  51. ESBATech Closes USD 41M Series B Venture Financing (esbatech.com) [edit]
Edit This Page
Last Edited 3/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy